Search Results - "Burris, Howard A 3rd"

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.

Authors: Perez, Edith A. de Haas, Sanne Lysbet Eiermann, Wolfgang et al.

Source: BMC Cancer. 5/30/2019, Vol. 19 Issue 1, p1-14. 14p. 1 Diagram, 4 Charts, 2 Graphs.

A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.

Authors: LoRusso, Patricia M. Infante, Jeffrey R. Kim, Kevin B. et al.

Source: BMC Cancer. 3/6/2017, Vol. 17, p1-13. 13p. 1 Diagram, 4 Charts, 1 Graph.

Combination chemotherapy with gemcitabine and vinorelbine in the treatment of patients with relapsed or refractory small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.

Authors: Hainsworth, John D. Burris III, Howard A. Erland, Joan B. et al.

Source: Cancer Investigation. Apr2003, Vol. 21 Issue 2, p193-199. 7p. 3 Charts.

Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE.

Authors: Perez, Edith A. Barrios, Carlos Eiermann, Wolfgang et al.

Source: Cancer (0008543X). Nov2019, Vol. 125 Issue 22, p3974-3984. 11p.

Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures.

Authors: Spigel, David R. Burris, Howard A. Greco, F. Anthony et al.

Source: Cancer (0008543X). Jun2018, Vol. 124 Issue 11, p2355-2364. 10p.

Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non-small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2.

Authors: Spigel, David R. Hainsworth, John D. Joseph, Mathew J. et al.

Source: Cancer (0008543X). May2018, Vol. 124 Issue 9, p1982-1991. 10p.

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.

Authors: IIIBurris, Howard A Flinn, Ian W Patel, Manish R et al.

Source: Lancet Oncology. Apr2018, Vol. 19 Issue 4, p486-496. 11p.

TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies.

Authors: Burris, Howard Kurkjian, C. Hart, L. et al.

Source: Cancer Chemotherapy & Pharmacology. Aug2017, Vol. 80 Issue 2, p261-273. 13p.

Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.

Authors: Perez, Edith A. de Haas, Sanne Lysbet Eiermann, Wolfgang et al.

Source: BMC Cancer. 6/24/2019, Vol. 19 Issue 1, pN.PAG-N.PAG. 1p. 1 Chart, 1 Graph.

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab.

Authors: Swanton C Madison RW Tambaoan CFB et al.

Source: Molecular oncology [Mol Oncol] 2025 Nov; Vol. 19 (11), pp. 3060-3078. Date of Electronic Publication: 2025 May 28.

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study

Journal Info: Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101308230 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0261 (Electronic) Linking ISSN: 15747891 NLM ISO Abbreviation: Mol Oncol Subsets: MEDLINE

A Phase II Study to Evaluate the Efficacy of Commercially Available Molecularly Matched Targeted Therapies in the Second-Line Setting.

Authors: Jones S Falchook G Graff S et al.

Source: The oncologist [Oncologist] 2026 Jul 22. Date of Electronic Publication: 2026 Jul 22.

Publication Type: Journal Article

Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE

Clinical Research in Community Oncology: Advancing Cancer Care Through Localized Clinical Trials.

Authors: Sturgill E Jones C Burris HA 3rd et al.

Source: JCO oncology practice [JCO Oncol Pract] 2026 Jul 01, pp. OP2500922. Date of Electronic Publication: 2026 Jul 01.

Publication Type: Journal Article

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101758685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2688-1535 (Electronic) Linking ISSN: 26881527 NLM ISO Abbreviation: JCO Oncol Pract Subsets: MEDLINE

Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma.

Authors: Dummer R Sandhu S Miller WH Jr et al.

Source: Future oncology (London, England) [Future Oncol] 2026 Apr; Vol. 22 (9), pp. 995-1013. Date of Electronic Publication: 2026 Mar 31.

Publication Type: Journal Article

Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE; In Process

Howard A. "Skip" Burris III, MD: an oncology pioneer reflects on patients, progress, and purpose.

Authors: Shaw ML Burris HA 3rd

Source: The American journal of managed care [Am J Manag Care] 2026 Feb; Vol. 32 (Spec. No. 2), pp. SP74-SP76.

Publication Type: Journal Article; Historical Article

Journal Info: Publisher: Clinical Care Targeted Communications Group, LLC Country of Publication: United States NLM ID: 9613960 Publication Model: Print Cited Medium: Internet ISSN: 1936-2692 (Electronic) Linking ISSN: 10880224 NLM ISO Abbreviation: Am J Manag Care Subsets: MEDLINE

The evolving landscape of tissue-agnostic therapies in precision oncology.

Authors: Subbiah V Gouda MA Ryll B et al.

Source: CA: a cancer journal for clinicians [CA Cancer J Clin] 2024 Sep-Oct; Vol. 74 (5), pp. 433-452. Date of Electronic Publication: 2024 May 30.

Publication Type: Journal Article; Review; Research Support, N.I.H., Extramural

Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0370647 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1542-4863 (Electronic) Linking ISSN: 00079235 NLM ISO Abbreviation: CA Cancer J Clin Subsets: MEDLINE

A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer.

Authors: Mayer EL Tayob N Ren S et al.

Source: Breast cancer research and treatment [Breast Cancer Res Treat] 2024 Feb; Vol. 204 (1), pp. 123-132. Date of Electronic Publication: 2023 Nov 29.

Publication Type: Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article

Journal Info: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE

Revolutionizing cancer drug development: Harnessing the potential of basket trials.

Authors: Subbiah V Burris HA 3rd Kurzrock R

Source: Cancer [Cancer] 2024 Jan; Vol. 130 (2), pp. 186-200. Date of Electronic Publication: 2023 Nov 07.

Publication Type: Journal Article; Review

Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma.

Authors: Dummer R Sandhu S Miller WH Jr et al.

Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2025 Jun 03; Vol. 31 (11), pp. 2097-2107.

Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study

Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study.

Authors: Gainor JF Patel MR Weber JS et al.

Source: Cancer discovery [Cancer Discov] 2024 Nov 01; Vol. 14 (11), pp. 2209-2223.

Publication Type: Journal Article; Clinical Trial, Phase I

Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE

Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.

Authors: Oh DY He AR Bouattour M et al.

Source: The lancet. Gastroenterology & hepatology [Lancet Gastroenterol Hepatol] 2024 Aug; Vol. 9 (8), pp. 694-704. Date of Electronic Publication: 2024 May 29.

Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101690683 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2468-1253 (Electronic) NLM ISO Abbreviation: Lancet Gastroenterol Hepatol Subsets: MEDLINE